NCT01495663View on ClinicalTrials.gov

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

January 31, 2014

Conditions
Cancer
Interventions
DRUG

I-131-CLR1404

"Description:~* Dosimetry: IV, 5 mCi, single dose, 6-day duration~* Therapy: IV, starting dose level of 12.5 mCi/m2, single dose, 56-day duration with follow up to one year"

Trial Locations (3)

53792

University of Wisconsin Hospital and Clinics, Madison

91010

City of Hope National Medical Center, Duarte

20007-2113

Georgetown University Hospital, Washington D.C.

Sponsors
All Listed Sponsors
lead

Cellectar Biosciences, Inc.

INDUSTRY

NCT01495663 - Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned | Biotech Hunter | Biotech Hunter